–Recently announced positive Phase 1 topline safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data show that intravenous (“IV”)...
Listing fees linked to the recent reverse takeover were significant. The post Safe Supply Posts Q4 Uplisting Costs Ahead of New Game Plan appeared first...
2023— the year that everyone in the psychedelic industry prepared for takeoff. Well, theoretical (but probable) take off. And, just a few weeks before...
-Intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as...
Psilocybe fungi, known colloquially as “magic mushrooms,” have held deep significance in Indigenous cultures of Mesoamerica for centuries. They captured...
MAPS Public Benefit Corporation (“MAPS PBC”), a company dedicated to transforming mental healthcare, announced an oversubscribed Series A financing....
–Recently announced positive Phase 2 topline data in Major Depressive Disorder (“MDD”) with 79% of patients in remission from depression after two...
The firm managed to find adequate research funding over the year as sale talks emerged. The post Tryp Therapeutics Lowers Losses in 2023; Sees New Era...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed The post News...
Tryp Therapeutics announces signing of definitive agreement with Exopharm Limited. The post Tryp Therapeutics To Be Acquired by Exopharm appeared first...